Myriad Genetics, BeiGene Ink CDx Pact

Apr 06, 2017

NEW YORK (GenomeWeb) – Myriad Genetics today announced a companion diagnostic development pact with BeiGene, a company developing cancer treatments combining immunotherapy and molecularly targeted drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Myriad Genetics' Breast Cancer Recurrence Test Wins Positive Coverage From Palmetto, Anthem
Biocept, UT Southwestern Partner for ALK Liquid Biopsy Study
Stanford-Developed Approach Allows for More Private Analysis of Human Genomes
Amebic Infection Severity May Decline as Gut Microbial Diversity Increases
Cynvenio, St. Luke's Partner on Breast Cancer Study
Roka Bioscience Sells Assets for $17.5M, Will Likely Liquidate

The Scan

The Apple's Journey

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

This Week in Nature

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Change Is Hard to Do

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

Possible Paths for CUP

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Main menu